Hidroxy 500 Injection contains Hydroxyprogesterone acetate 500 mg per dose, a synthetic derivative of the naturally occurring hormone progesterone. It is primarily indicated for the prevention of preterm birth in women with a history of spontaneous preterm delivery and for the management of secondary amenorrhea. Hydroxyprogesterone exerts its effects by modulating the endometrial lining, maintaining pregnancy, and reducing uterine contractility. Administered via intramuscular injection, Hidroxy 500 provides sustained progestogenic activity, supporting the maintenance of pregnancy in high-risk cases. The pharmacological action involves binding to progesterone receptors, leading to alterations in gene expression that promote uterine quiescence and inhibit inflammatory processes implicated in preterm labor. Dosage and administration should be strictly adhered to as per clinical guidelines, typically involving weekly injections starting from the second trimester until 36 weeks of gestation or delivery. Contraindications include known hypersensitivity to hydroxyprogesterone or any component of the formulation, active thrombophlebitis, liver dysfunction, and undiagnosed vaginal bleeding. Common adverse effects may include injection site reactions, headache, nausea, and fluid retention. Caution is advised in patients with a history of thromboembolic disorders. Hidroxy 500 Injection should be used under the supervision of a qualified healthcare professional with appropriate monitoring.